Purpose: To investigate how the optical density ratio (ODR) of subretinal fluid (SRF) obtained by optical coherence tomography (OCT) in eyes with chronic central serous retinopathy (CSR), defined as symptoms >3 months, treated with eplerenone correlates with treatment response and visual outcomes. Methods: This retrospective, single-center observational study included patients with chronic CSR treated with eplerenone who had at least 6 weeks of follow-up. Eyes with poor-quality OCT scans, shallow SRF precluding sampling of optical density (OD), and macular pathology other than CSR were excluded. Optical density of the vitreous and SRF was measured using ImageJ and used to calculate ODR (ODR ¼ OD SRF /OD VIT ). Peak SRF height, foveal SRF height, central macular thickness (CMT), and Snellen visual acuity (VA) were measured. The Mann-Whitney U test was used to compare continuous variables. Pearson correlation coefficient was used to determine the statistical significance of applied linear regressions. Results: Twenty-three eyes of 23 patients met the inclusion criteria. Six (26%) eyes had complete resolution of foveal SRF (resolvers) with eplerenone treatment, and the remainder of patients had worsening or incomplete resolution (nonresolvers). Resolvers had significantly lower baseline logarithm of the minimum angle of resolution (logMAR) VA (P < .01) than nonresolvers. There was a positive linear correlation between ODR and logMAR VA at baseline (R 2 ¼ 0.208; P ¼ .03) and follow-up (R 2 ¼ 0.206; P ¼ .03). A significant correlation between ODR and percentage change in CMT was found (R 2 ¼ 0.263; P ¼ .01). Linear correlations were not found between ODR and age, peak SRF height, and foveal SRF height (all P > .125). Conclusion: Lower baseline ODR was associated with improved percentage change in CMT and VA in patients treated with eplerenone for chronic CSR. Optical density ratio may represent a novel prognostic biomarker that may help determine which eyes with chronic CSR may respond better to eplerenone.
Introduction
Submacular fluid in central serous retinopathy (CSR) can cause central vision loss, metamorphopsia, dyschromatopsia, and micropsia. Central serous retinopathy typically affects patients aged between 20 and 50 years, and associations with a "type A" personality trait, corticosteroids, phosphodiesterase inhibitors, and testosterone are well described. [1] [2] [3] [4] [5] Most cases are idiopathic with spontaneous resolution of subretinal fluid (SRF) and recovery of visual acuity (VA) in approximately 80% of eyes. However, up to 20% of eyes have persistent submacular fluid for more than 3 months and are defined as having chronic CSR. 6 As eyes with chronic CSR are at risk of persistent vision loss due to damage to the retinal pigment epithelium (RPE), treatments including thermal laser and photodynamic therapy with verteporfin have been used with variable success. The association of CSR with both exogenous and endogenous corticosteroids has led to interest in the mineralocorticoid receptor pathway as a potential therapeutic target. 7 In several small studies, eplerenone (Inspra; Pfizer, New York, New York), a commercially available mineralocorticoid antagonist, has been shown to improve anatomic and visual outcomes, presumably via mediation of choroidal vascular permeability. [8] [9] [10] [11] [12] Despite these promising results, a number of patients with chronic CSR do not respond to treatment.
The composition of SRF in many diseases associated with macular detachment, including CSR, is unknown. 13 Optical coherence tomography (OCT) allows clinicians to noninvasively visualize retinal anatomy and quantify SRF. Optical coherence tomography also enables quantitative analysis of light reflectivity profiles, or optical density (OD), of specific anatomic structures and potential spaces.
14 A high optical density ratio (ODR) is associated with higher SRF reflectivity and is postulated to correlate with increased protein concentration in SRF. 15, 16 The ODR, defined as the ratio of SRF OD to vitreous OD, is a measure of light reflectivity that controls for anterior anatomic variables of light refraction such as corneal, lens, and vitreous pathology.
Prior studies have shown that the ODR of SRF in RRD increases over time, suggesting a change in the SRF composition and introducing the idea that ODR may be useful in monitoring the course and nature of macular disease. 16, 17 One of those studies showed that lower ODR also correlates with better VA at 3 months. 17 In eyes with neovascular agerelated macular degeneration (nAMD), increased ODRs were correlated with increased treatment burden. 18 These studies of ODR in RRD and nAMD show an association between ODR, time, and visual outcomes, which may lead one to hypothesize whether ODR may be utilized as a prognostic marker of disease activity and treatment response.
Given the variable response of many patients with chronic CSR to mineralocorticoid inhibitors, the purpose of this study is to examine the potential correlation between ODRs, VA, and treatment response in patients treated with eplerenone for chronic CSR.
Methods

Patient Selection and Data Collection
The institutional review board of Wills Eye Hospital approval was obtained for this single-center retrospective study. Electronic billing records were used to identify consecutive patients with CSR (International Classification of Diseases, ninth revision code 362.41 and 10th revision code H35.7) who were treated with eplerenone and had spectral domain optical coherence tomography (SD-OCT) performed between January 1, 2014, and March 1, 2016. Exclusion criteria included acute CSR (symptoms or documented SRF <3 months), lack of follow-up with OCT (<6 weeks), poor-quality OCT (Q score <15), shallow SRF precluding sampling of OD, and media opacity that could affect VA. Eyes with hyperreflective subretinal opacities or material, fibrinoid fluid, and choroidal neovascular membranes were excluded from our study. For patients who experienced bilateral CSR, a random number generator was used to select a single eye for study inclusion. Demographic data, medical history, ocular history, eplerenone dose, and examination findings were recorded.
Optical Coherence Tomography Scanning Protocol Scans
All SD-OCT scans were performed by certified ophthalmic photographers. All SD-OCT scans were obtained with the Heidelberg Spectralis HRA þ OCT (Heidelberg Engineering, Heidelberg, Germany) with eye tracking Automatic Real-Time Function set to 9 and high-speed mode. The patient's baseline OCT scan on the day eplerenone was prescribed and follow-up OCT scan obtained at least 6 weeks after starting eplerenone were used for analysis. Optical coherence tomography scan quality of the same eye will generally vary from visit to visit. This is controlled for by using the ODR with the vitreous serving as an internal control for image quality and light reflectivity as opposed to only the OD of SRF which is sensitive to OCT image quality. Additionally, OCT images with Q score <15 were not used to avoid any artifactual changes to ODR.
Image Analysis and ODR Measurements
The OCT image with the largest volume of SRF and the highest Q score (calculated from the signal-to-noise ratio) was analyzed and data extracted, regardless of its proximity to the fovea. If several OCT images were similar in volume, the image with the highest Q score was used for analysis. Peak SRF height (highest displacement of retina from the RPE) and foveal SRF height (displacement of retina from the RPE at the fovea) were measured manually. Central macular thickness (CMT) measurements were extracted from Heidelberg software. Images were exported as compression-free, highestquality JPEG format images.
The OD of SRF and vitreous were measured using ImageJ (National Institutes of Health, Bethesda, Maryland) for each OCT scan as previously described.
1,2 Briefly, two 30 Â 10 pixel regions of interest (ROIs) were chosen, 1 from the center of SRF and 1 from the vitreous. Regions of interest were chosen to avoid any fluid-tissue interfaces, debris/floaters, vitreous hemorrhage, and other artifacts. Subretinal fluid ROI were chosen so that the corresponding vitreous ROI did not coincide with the posterior hyaloid. To control for light refraction and other variables that can affect OD such as corneal, lens, and vitreous pathology, the vitreous ROI was collected 50 pixels above the internal limiting membrane (ILM) in the same vertical line immediately above the SRF ROI. If the OCT scan did not allow for sampling of vitreous 50 pixels above the ILM, the closest sample to 50 pixels was taken. For example, in cases where the vitreous ROI coincided with the posterior hyaloid or vitreous debris, the ROI OD was measured either above or below so as to avoid the opacity. The ODR of SRF (OD SRF ) to vitreous (OD VIT ) was then calculated as follows: ODR ¼ OD SRF /OD VIT .
Statistical Analysis
Statistical analysis was performed with SPSS V.22 (IBM, Armonk, New York). Summary statistics of mean with standard deviation of continuous variables and tests of normality were calculated. Best available Snellen VA (with correction or pinhole) was converted into its logarithm of the minimum angle of resolution (logMAR) equivalent. The change in CMT, peak SRF height, and foveal SRF height were calculated. The nonparametric, 2-tailed Mann-Whitney U test was used to compare continuous variables, and the Pearson correlation coefficient was used to determine statistical significance of applied linear regressions. Significance was defined as a P value of <.05.
Results
A total of 23 consecutive patients (23 eyes) with chronic CSR were included in this study. Baseline demographic data are presented in Table 1 . Of the 23 eyes, 9 (39%) were treated with 25 mg eplerenone, 12 (52%) were treated with 50 mg eplerenone, and 2 (9%) were started on 25 mg and then increased to 50 mg. Additional cohorts for subgroup analysis were defined as: eyes with complete resolution of foveal SRF after eplerenone (resolvers; n ¼ 6 eyes) and eyes with persistent foveal SRF after eplerenone (nonresolvers; n ¼ 17 eyes). Central macular thickness data were available for 19 of 23 eyes; n ¼ 19 for all CMT analyses.
Baseline Versus Follow-Up
On average, there was a statistically significant improvement in CMT, peak SRF height, foveal SRF height, and logMAR VA (all P < .02) comparing baseline to posttreatment OCTs. Optical density ratio did not change significantly from baseline to posttreatment OCT (all P >.12, Table 2 ).
Logistic Regressions With ODR
There was a positive, statistically significant correlation between ODR and logMAR VA, both at baseline (R 2 ¼ 0.208; P ¼ .03) and follow-up (R 2 ¼ 0.206; P ¼ .03). There was a nonsignificant trend toward improvement in CMT with decreasing ODR (R 2 ¼ 0.145; P ¼ .07). Consistent with this, decreased ODR trended with greater improvement in peak SRF and foveal SRF; however, these trends were similarly nonsignificant (all P > .125). A linear correlation was not found between ODR and age, baseline peak SRF, or baseline foveal SRF (all P > .125). We postulated that a ceiling effect may have masked potential univariate correlations between ODR and anatomic change. Accordingly, we found that ODR and percentage change in CMT were indeed highly correlated (R 2 ¼ 0.263; P ¼ .01).
Resolvers Versus Nonresolvers
Of 23 eyes with foveal SRF on presentation, 6 (26%) eyes had complete resolution of foveal SRF (resolvers), whereas 17 (74%) eyes did not (nonresolvers; Table 3 ). The baseline ODR in the resolvers group was lower than the nonresolvers group but not significantly so (P ¼ .11; Figures 1 and 2) . The change in foveal SRF was significantly greater in the resolvers group compared to the nonresolvers group (P < .01). There was a significant difference in baseline logMAR VA between cohorts (P < .01).
Discussion
This study suggests that lower ODR may be associated with greater anatomic and visual treatment response to eplerenone in eyes with chronic CSR. Conversely, a higher ODR may be associated with a less robust response to eplerenone therapy. Increased ODR may reflect a combination of higher SRF protein concentration, increased RPE dysfunction, and increased permeability of the blood-retina barrier, resulting in slower resolution and/or response to treatment. Our data demonstrate that in eyes with chronic CSR, there is no difference in ODR at baseline versus at final follow-up after treatment with eplerenone (P ¼ .12). This is consistent with previous data which show that there was no significant difference between the ODR in acute and chronic CSR (P ¼ .36). 15 These data suggest that ODR is not necessarily a reliable measure of chronicity or duration of symptoms in patients with CSR. This is in contrast to SRF in RRD, in which light reflectivity of SRF was shown to increase with time. 16, 17 Kashani hypothesized that increased ODR may be a result of a higher concentration of photoreceptor outer segment fragments that remain suspended in SRF after serous fluid is resorbed. 16 Similar to prior work on eyes with RRD and AMD, 17, 19 we found that ODR had a positive correlation with presenting logMAR VA (R 2 ¼ 0.208, P ¼ .03) and follow-up logMAR VA (R 2 ¼ 0.206, P ¼ .03). This supports the idea that OD of SRF may be a marker of disease activity and its associated secondary effects leading to visual loss. 19 Our finding that anatomic improvement (percentage improvement in baseline CMT) after treatment with eplerenone was associated with lower ODR bolsters this supposition (R 2 ¼ 0.263; P ¼ .01).
Other potential biomarkers for CSR have been investigated. Outer nuclear layer thickness at the fovea has been shown to correlate with best-corrected visual acuity (BCVA) in eyes with resolved central serous chorioretinopathy (CSCR), 20 and total foveal thickness has been correlated with BCVA in eyes with chronic CSCR. 21 Reduced choroidal thickness has not yet been shown to have prognostic significance but is associated with resolution of CSR. 22 In contrast to studies of the retinal anatomy, a high ODR is associated with higher SRF reflectivity and is postulated to correlate with increased protein concentration in SRF. 15 Optical density ratios have been found to highly differentiate between eyes with choroidal neovascular membranes and those with CSR and has been used to distinguish SRF in nAMD, RRD, CSR, and polypoidal choroidal vasculopathy. 14, 15 Optical density ratios have also been found to correlate with both treatment interval and visual outcomes in eyes with nAMD and visual outcomes following retinal detachment repair. 17, 19 However, to the best of our knowledge after a systematic literature search on PubMed and Ovid Medline with the terms "central serous retinopathy" and "optical density," no prior studies have examined ODR as a functional and an anatomic prognostic biomarker for patients treated with eplerenone for chronic CSR.
The strengths of the current study include its novel analysis of ODRs in the context of treatment response for CSR and relatively long follow-up time for all included patients. Limitations include its retrospective nature, nonstandardized followup time, and variability in eplerenone dosing. Most eyes (21 eyes, 91%) were maintained on a constant dose of eplerenone, and the majority of eyes were treated with 50 mg eplerenone (12 eyes, 52%). No significant difference was found between eplerenone dosing in the resolver versus nonresolver groups (P ¼ .27). With regard to OD measurement, sampling error is a source of potential error given that 1 ROI was used for sampling as opposed to an average of several ROI samples. However, the OD of SRF using an ROI compared to the OD averaged over the entire area of SRF has been shown to be statistically similar. 14, 19 There are several anatomic variables that affect light reflectivity and OD measurement such as tear film quality, lens status, vitreous syneresis, and posterior vitreous detachment status. The advantage of utilizing ODR measurements over absolute OD measurements is that calculating a ratio of OD reflectivity normalizes the optical effect of anterior ocular structures between different eyes. 14, 17, 19 Although patients with acute CSR typically are in the age range of 20 to 50 years old, the mean age of our study population with chronic CSR was 56 years. The univariate linear correlations found between ODR, VA, and percentage improvement in CMT were robust, but the lack of BCVA and modest sample size may have limited our ability to detect the impact of other factors (age, height of serous detachment, and eplerenone dose) on anatomic and visual recovery. Given the univariate trends of our data set, a larger sample size may have indeed revealed a statistically significant differential when comparing ODRs of patients with complete resolution of SRF versus those who had incomplete resolution. Larger prospective studies that include microperimetry, BCVA, and patients with both acute and chronic CSR would be needed to address some of these limitations.
In conclusion, lower baseline ODR was associated with an improved percentage change in CMT and VA in patients treated with eplerenone for chronic CSR. Increased ODR in CSR could reflect a more porous blood-retina barrier, more proteinaceous SRF, and increased RPE dysfunction, suggesting a lower likelihood of treatment response and worsened acuity. Optical density ratio of SRF may represent a novel prognostic biomarker in eyes with chronic CSR treated with eplerenone.
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